RSV is the leading cause of hospitalization in Canadian infants, yet many remain unprotected after leaving the hospital. In this quick 5-minute session, Dr. Jane Healey shares simple, evidence-based ways for healthcare providers to close protection gaps by incorporating nirsevimab (Beyfortus) into routine newborn and well-baby visits, helping ensure every infant is protected throughout the RSV season.
This program has received an unrestricted educational grant or in-kind support from Sanofi Canada.